Loading...
Congenital methemoglobinemia type II: Clinical improvement with short-term methylene blue treatment
Cooper, Monica S. Randall, Melinda Rowell, Margaret Charlton, Margaret Greenway, Anthea Barnes, Chris D.
Cooper, Monica S.
Randall, Melinda
Rowell, Margaret
Charlton, Margaret
Greenway, Anthea
Barnes, Chris D.
Abstract
We report a case of prophylactic management with methylene blue (MB) in an almost 4‐year‐old male with congenital methemoglobinemia type II. He has a CYB5R3 compound heterozygote mutation, causing a cytochrome‐b(5) reductase deficiency. Since the MB treatment regimen has commenced, his methemoglobin level has been significantly lower. He has shown modest behavioral improvements (as assessed on the Achenbach behavior report scales). There have been no iatrogenic side effects. These findings are encouraging for symptomatic improvement with regular prophylactic MB treatment but represent a single case report, which must be interpreted with caution.
Keywords
methemoglobinemia, methemoglobin, cytochrome-b(5)reductase, methylene blue, cyanosis
Date
2016
Type
Journal article
Journal
Pediatric Blood and Cancer
Book
Volume
63
Issue
3
Page Range
558-560
Article Number
ACU Department
Collections
Relation URI
Source URL
Event URL
Open Access Status
License
File Access
Controlled